Ensartinib Hydrochloride Patent Expiration
Ensartinib Hydrochloride was first introduced by Xcovery Holdings Inc
Ensartinib Hydrochloride Patents
Given below is the list of patents protecting Ensartinib Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ensacove | US10899744 | Crystalline form of compound suppressing protein kinase activity, and application thereof | Jun 01, 2037 | Xcovery |
| Ensacove | US9126947 | Substituted pyridazine carboxamide compounds | Nov 29, 2031 | Xcovery |
| Ensacove | US9296724 | Substituted pyridazinecarboxamides as kinase inhibitors | Jun 18, 2029 | Xcovery |
| Ensacove | US8551995 | Kinase inhibitor compounds | Feb 09, 2029 | Xcovery |
Ensartinib Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List